Witt O - Search Results

1

Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.

Ecker J, Thatikonda V, Sigismondo G, Selt F, Valinciute G, Oehme I, Müller C, Buhl JL, Ridinger J, Usta D, Qin N, van Tilburg CM, Herold-Mende C, Remke M, Sahm F, Westermann F, Kool M, Wechsler-Reya RJ, Chavez L, Krijgsveld J, Jäger N, Pfister SM, Witt O, Milde T. Ecker J, et al. Among authors: witt o. Neuro Oncol. 2021 Feb 25;23(2):226-239. doi: 10.1093/neuonc/noaa191. Neuro Oncol. 2021. PMID: 32822486 Free PMC article.

2

Multifocal osteochondroma after repeated irradiation in a boy with Hodgkin disease.

Milde T, Alamo L, Stadelmann C, Schweigerer L, Witt O. Milde T, et al. Among authors: witt o. J Pediatr Hematol Oncol. 2005 Jun;27(6):344-5. doi: 10.1097/01.mph.0000170886.20335.cb. J Pediatr Hematol Oncol. 2005. PMID: 15956892 No abstract available.

3

Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.

Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, Schwab M, Witt O. Deubzer HE, et al. Among authors: witt o. Int J Cancer. 2008 Apr 15;122(8):1891-900. doi: 10.1002/ijc.23295. Int J Cancer. 2008. PMID: 18074352 Free article.

4

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.

Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O. Deubzer HE, et al. Among authors: witt o. Cancer Lett. 2008 Jun 8;264(1):21-8. doi: 10.1016/j.canlet.2008.01.002. Epub 2008 Feb 8. Cancer Lett. 2008. PMID: 18262346

5

Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.

Wegener D, Hildmann C, Riester D, Schober A, Meyer-Almes FJ, Deubzer HE, Oehme I, Witt O, Lang S, Jaensch M, Makarov V, Lange C, Busse B, Schwienhorst A. Wegener D, et al. Among authors: witt o. Biochem J. 2008 Jul 1;413(1):143-50. doi: 10.1042/BJ20080536. Biochem J. 2008. PMID: 18384290

6

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.

Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O. Wegener D, et al. Among authors: witt o. Anticancer Drugs. 2008 Oct;19(9):849-57. doi: 10.1097/CAD.0b013e32830efbeb. Anticancer Drugs. 2008. PMID: 18765999

7

HDAC family: What are the cancer relevant targets?

Witt O, Deubzer HE, Milde T, Oehme I. Witt O, et al. Cancer Lett. 2009 May 8;277(1):8-21. doi: 10.1016/j.canlet.2008.08.016. Epub 2008 Sep 27. Cancer Lett. 2009. PMID: 18824292 Review.

8

Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma.

Milde T, Pfister S, Korshunov A, Deubzer HE, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von Deimling A, Witt O. Milde T, et al. Among authors: witt o. Genes Chromosomes Cancer. 2009 Mar;48(3):229-38. doi: 10.1002/gcc.20635. Genes Chromosomes Cancer. 2009. PMID: 19025795

9

Histone deacetylase 8 in neuroblastoma tumorigenesis.

Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. Oehme I, et al. Among authors: witt o. Clin Cancer Res. 2009 Jan 1;15(1):91-9. doi: 10.1158/1078-0432.CCR-08-0684. Clin Cancer Res. 2009. PMID: 19118036

10

Targeting histone deacetylases in neuroblastoma.

Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I. Witt O, et al. Curr Pharm Des. 2009;15(4):436-47. doi: 10.2174/138161209787315774. Curr Pharm Des. 2009. PMID: 19199971 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

255 results

Search Page